- Home
- MTNB vs GLMD Comparison
MTNB vs GLMD Comparison
Compare MTNB & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | GLMD |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.2M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MTNB | GLMD |
|---|---|---|
| Price | $0.18 | $3.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 921.9K | 62.8K |
| Earning Date | 05-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,750.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.41 |
| 52 Week High | $2.14 | $5.45 |
Technical Indicators
Market Signals| Indicator | MTNB | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 72.35 |
| Support Level | $0.18 | $0.54 |
| Resistance Level | $0.27 | $5.45 |
| Average True Range (ATR) | 0.02 | 0.36 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 8.53 | 70.81 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.